Register
Login:
Share:
Email Facebook Twitter


ASCENT RESOURCES: Gas flows mean cash flows to develop up to 15 wells


BTG Share Chat (BTG)



Share Price: 715.00Bid: 715.00Ask: 715.50Change: 0.00 (0.00%)No Movement on Btg
Spread: 0.50Spread as %: 0.07%Open: 711.50High: 716.50Low: 708.00Yesterday’s Close: 715.00


Share Discussion for BTG


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


NickLyon
Posts: 7
Off Topic
Opinion:No Opinion
Price:716.00
wrong site
Fri 15:38
Oops that should have been for the PMG site
 
NickLyon
Posts: 7
Off Topic
Opinion:No Opinion
Price:716.50
iii - comment
Fri 15:37
Results today from Parkmead (PMG) where increased production from the Diever West gas field to 39.3 million cubic feet a day gives positive cash flow and greater returns. Cash is a pleasing $34.3 million (£26 million) and Tom Cross is maintaining his usual strict discipline.

For right or for wrong he has increased his position in the Greater Perth area and activity covering pre-FEED and FEED is under way. I took PMG out of the bucket list in February at over 60p, as I couldnt see the market liking the play as much as others, at 37p today I still need convincing that they offer substantial value.
RevoltingPeasant
Posts: 37
Observation
Opinion:Buy
Price:696.00
Investors Chronicle (again)
Tue 13:30
IC on line bulletin today has BTG as a buy again following this morning's results
RevoltingPeasant
Posts: 37
Observation
Opinion:Buy
Price:720.00
Investors Chronicle
8 Nov '17
Positive piece in today's on line IC report. Even allowing for the legal decision, BTG still materially undervalued:

BTG£s (BTG) varicose veins treatment Varithena has finally been assigned a permanent insurance code in the US. Doctors who implement the procedure will be entitled to up to $1,697 (£1,292) reimbursement via the government£s Medicare and Medicaid insurance programmes, meaning prescription is now expected to pick up.

Varithena insurance has been the thorn in BTG£s side since 2015 when the treatment was first launched in the US. Originally, its temporary code meant doctors could only expect up to $1,129 back from the insurers, short of the $3,000 it costs for use on multiple veins. Without guaranteed reimbursement, doctors have been reluctant to prescribe Varithena and sales have fallen far short of expectations during the past two years.

But even with these new codes, broker Panmure Gordon remains cautious about forecasting an uptick in sales due to competition in the market. And even chief executive Louise Makin is still reluctant to get excited, warning that the impact on physician adoption and insurer practice might not become clear before the end of 2018.

Investor enthusiasm for the announcement was also dampened by news that BTG will have to take a £53.5m provision in its upcoming first-half results due to problems surrounding another product. A Delaware court has found the group guilty of breaching the terms of its distribution agreement with peer WellStat, regarding chemotherapy toxicology treatment Vistogard. WellStat claimed the UK group had failed to invest in a large enough sales force in the US. BTG has been forced to pay damages and will lose the US rights to the treatment. BTG is considering its appeal options. Considering Vistogard only contributed £3.5m of sales in the year to March 2017, this news won£t have muddied the outlook too much. However, the one-off provision is sure to impact half-year results, due on 14 November.

IC View

Poor publicity regarding a small number of insignificant drugs has dogged BTG£s share price for the past few years. The shares are up on solidly our recent buy tip (652p, 25 May 2017). Although some sentiment has been recovered by the promise of new Varithena codes, we think the shares£ forward earnings valuation of 25 times £ far below the top of its five-year valuation range £ fails to account for the growth available in some of BTG£s key markets. Buy."
MickTKipper
Posts: 2,452
Off Topic
Opinion:Strong Buy
Price:748.50
BTG Report Interims 14th NOV
2 Nov '17
BTG...pushing on up to Interims on the 14th Nov. EPS seen increasing 84% and P/E of 25 to 2018, (Hist Low)Numis have a 900p SP Target 😎😃

https://pbs.twimg.com/media/DNnV021XUAAeVHp.jpg
MickTKipper
Posts: 2,452
Off Topic
Opinion:Strong Buy
Price:754.50
RE: BTG
20 Oct '17
volcano
Posts: 3,388
Off Topic
Opinion:No Opinion
Price:748.00
BTG
18 Oct '17
FTSE 100 one day ,
trend364
Posts: 95
Off Topic
Opinion:No Opinion
Price:746.50
RE: .
18 Oct '17
A couple of quid up on last year though when it felt more like a breakDOWN
bloody
Posts: 46
Off Topic
Opinion:No Opinion
Price:749.00
.
18 Oct '17
How many different forums are you posting that message....
MickTKipper
Posts: 2,452
Off Topic
Opinion:Strong Buy
Price:742.50
BTG, Yearly Chart Breakout.........
18 Oct '17
BTG Btg yearly and 6 month breakout. Brokers have been bullish recently. eg, 05 Oct 17 Numis Buy 741.00 900.00 900.00 Reiterates.

Broker Upgrade ---

17-Oct-2017 05:16:40 - BTG PLC BTG.L:

JEFFERIES RAISES TARGET PRICE TO 900P FROM 775P;

RATING BUY.

http://uk.advfn.com/p.php?pid=legacydaily&epic=L^BTG&type=4&size=2&period=5&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=25&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=200&o_2maday2=&o_colour2=2&scheme=&delay_indices=DELAYED_INDICES




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.